A Retrospective Cohort Analysis of SMARCA4-Deficient Lung Cancer

A Real-World Retrospective Cohort Analysis of SMARCA4-Deficient Advanced Lung Cancer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07121387

Enrollment

221

Registered

2025-08-13

Start date

2020-01-01

Completion date

2024-12-17

Last updated

2025-08-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NSCLC (Advanced Non-small Cell Lung Cancer), SMARCA4-Deficient Tumor

Brief summary

This is a single-center retrospective analysis to explore the clinical characteristics, therapeutic efficacy, and tumor immune microenvironment of SMARCA4-deficient advanced non-small-cell lung cancer (NSCLC).

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Diagnosed with stage III-IV NSCLC according to the American Joint Committee on Cancer staging criteria (7th edition); * Lesions are measurable according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; * Receiving first-line immunotherapy or chemotherapy as anti-tumor treatment.

Exclusion criteria

* SMARCA4 gene test was not performed; * Not receive treatment; * Lost to follow-up after one treatment cycle.

Design outcomes

Primary

Measure	Time frame	Description
Progression-free survival (PFS)	5 years	Time from the beginning of first-line therapy to the first progression (PD) in patients with lung cancer

Secondary

Measure	Time frame	Description
Overall survival (OS)	5 years	Overall survival (OS) is defined as the duration from the beginning of first-line therapy until death due to any cause. Subjects who are still alive at the end of the study observation period will be censored at the time of last known vital status.
Objective Response Rate (ORR)	5 years	The proportion of patients with a complete response or partial response to treatment according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
Disease control rate (DCR)	5 years	Disease control rate (DCR) was defined as the proportion of patients achieving complete response (CR), partial response (PR), or stable disease (SD) according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1).

Other

Measure	Time frame	Description
The correlation between tumor immune microenvironment and therapeutic efficacy	5 years	Multiplex immunofluorescence staining was performed on pathological specimens from individuals diagnosed with SMARCA4-deficient lung cancer who underwent immune combination chemotherapy.

Countries

China

Outcome results